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Abstract
Objective—Most prior studies on aggressive end-of-life care in older patients with cancer have 
accounted for social determinants of health (e.g., race, income, and education), but rarely for 
multimoribidity (MM). In this study, we examine the association between end-of-life care and 
each of the social determinants of health and MM, hypothesizing that higher MM is associated 
with less aggressive care.
Methods—From the linked 1991–2008 Health and Retirement Study, Medicare data, and the 
National Death Index, we identified fee-for-service patients age ≥66 years who died from cancer 
(n = 835). MM was defined as the occurrence or co-occurrence of chronic conditions, functional 
limitations, and/or geriatric syndromes. Aggressive care was based on claims-derived measures of 
receipt of cancer-directed treatment in the last two weeks of life; admission to the hospital and/or 
emergency department (ED) within the last month; and in-hospital death. We also identified 
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patients enrolled in hospice. In multivariable logistic regression models, we analyzed the 
associations of interest, adjusting for potential confounders.
Results—While 61.2% of the patients enrolled in hospice, 24.6% underwent cancer-directed 
treatment; 55.1% were admitted to the hospital and/or ED; and 21.7% died in the hospital. We 
observed a U-shaped distribution between income and in-hospital death. Chronic conditions and 
geriatric syndromes were associated with some outcomes, but not with others.
Conclusions—To improve quality end-of-life care and curtail costs incurred by dying patients, 
relevant interventions need to account for social determinants of health and MM in a nuanced 
fashion.
Keywords
Social determinants of health; Chronic conditions; Functional limitations; Geriatric syndromes; 
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1. Introduction
In patients dying from cancer, receipt of aggressive care, including receipt of cancer-directed 
treatment, admission to an inpatient hospital and/or to the emergency department (ED), and 
in-hospital death, is considered an important indicator of poor-quality end-of-life care [1,2]. 
In addition, aggressive care is an important driver of health care costs [3], though it does not 
always yield benefits relative to cure or extension of life [4]. Conversely, palliative and 
hospice care provide a venue for pain management and symptom relief, as well as emotional 
and spiritual support, which may be beneficial to the patient and his/her family [5–7].
Variations in quality markers of end-of-life care have been observed across physicians [8,9], 
health centers [10], geographical regions [11–14], and various subgroups of the population 
[9,15–18]. In particular, racial/ethnic disparities both in receipt of aggressive care and 
hospice use have been documented extensively. Indeed, compared to others, minority 
patients are more likely to choose aggressive care [19] or to be hospitalized after being 
enrolled in hospice [20], and less likely to enroll in hospice care [17,21–24]. However, 
seldom have previous studies examined disparities in the specific context of geriatric 
patients with cancer presenting with multimorbidity (MM), defined here as the co-
occurrence of not only chronic conditions but also functional limitations and geriatric 
syndromes [25]. Functional limitations include limitations in strength and mobility, as well 
in activities of daily living and instrumental activities of daily living. Geriatric syndromes 
include such conditions as cognitive impairment, depressive symptoms, incontinence, and 
sensory impairment.
MM is (a) highly prevalent in older adults with cancer [26], and (b) more prevalent in 
minority than in non-minority patients [25]. Given that “do not resuscitate” orders are 
associated with chronic conditions and/or cognitive impairment [27], patients with higher 
burden of MM may be less likely to receive aggressive end-of-life care, and more likely to 
enroll in hospice.
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Using a unique data resource, developed by linking data from the Health and Retirement 
Study, Medicare enrollment and claims files, and the National Death Index, this study aims 
at gaining a better understanding of the correlates of aggressive end-of-life care and hospice 
use in older adults dying from cancer, by accounting for both social determinants of health 
and MM. We hypothesized that aggressive end-of-life care is independently associated with 
each of social determinants of health and MM.
Elucidating these associations could establish the need for and provide the basis to relevant 
interventions tailored to patients' sociodemographics and the level of complexity of their 
clinical presentation. Such interventions may help to curtail use of aggressive care and costs 
incurred by terminally ill patients with cancer.
2. Methods
We used the 1992–2008 linked Health and Retirement Study (HRS), National Death Index 
(NDI), and Medicare data. The study was approved by the University of Michigan, which 
maintains the HRS, the privacy board of the Centers for Medicare and Medicaid Services 
(CMS), and the Institutional Review Board, University Hospitals of Cleveland.
3. Data Sources
3.1. The Health and Retirement Study (HRS)
Funded by the National Institute on Aging, the HRS includes longitudinal data on a 
nationally representative sample of over 30,000 non-institutionalized older adults born in 
1953 and earlier. At each interview, which is conducted every two years, self-reported data 
are collected on a number of domains, including (but not limited to) health and functional 
status, chronic medical conditions, cognitive status, depressive symptoms, and 
sociodemographic characteristics.
We used data from the last HRS interview prior to death to obtain our measures of interest, 
including multimorbidity.
3.2. The National Death Index (NDI)
The NDI consists of a compilation of death certificate data that are obtained from all states, 
thus making it possible to ascertain HRS participants' vital status regardless of their state of 
residence.
The key variables that were retrieved from the NDI were date of death (in month and year), 
and the underlying cause of death, documented in International Coding of Diseases (ICD)—
in the 9th edition for deaths that occurred in 1999 or before, and in the 10th edition for 
deaths that occurred thereafter.
3.3. Medicare Enrollment and Claims Data
The enrollment file, which is organized at the individual level, carries the beneficiary's 
demographic variables (age, race, sex), as well as monthly variables indicating their 
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enrollment in managed care programs, making it possible for us to identify and exclude 
managed care enrollees.
The claims data include the Medicare Provider, Analysis, and Review (MedPAR) file, the 
Inpatient Standard Analytic File (SAF), the Outpatient SAF, the Carrier SAF, and Hospice 
SAF. Records in these files carry the service dates, as well as diagnosis and procedure codes. 
Diagnosis codes are documented in ICD-9; procedure codes are recorded in ICD-9, 
Common Procedural Terminology, 4th Edition (CPT-4), or Healthcare Common Procedural 
Coding System (HCPCS).
We used the Hospice SAF to identify study participants who used hospice at the end of life.
3.4. File Linkage
The above data sources (HRS, NDI, and Medicare data) were linked by HRS and Medicare. 
The files sent to us included dummy identifiers that do not carry any string of name, date of 
birth, or social security number, thus making it virtually impossible to identify a given 
participant. The same dummy identifier was used over time to be able to follow an 
individual longitudinally. A cross-reference file was provided to identify the same individual 
across the three different sources.
4. Study Population
Our study population consisted of HRS participants who died from cancer, as identified 
from the cause of death documented in the NDI (n = 2403). In order to ensure complete 
Medicare claims history, we limited our study subjects to those 66 years of age or older, and 
receiving their care exclusively through the traditional fee-for-service system (n = 835).
5. Variables of Interest
5.1. Dependent Variables
Following were our dependent variables: (1) receipt of cancer-directed treatment with 14 
days of death, including diagnostic and therapeutic procedures (for certain cancers only), 
chemotherapy, and radiation therapy (see relevant codes in the Appendix A); (2) multiple 
acute care visits within 30 days of death, including hospitalization and visits to the 
emergency department (ED), or at least one hospitalization with a stay of 14 days or longer. 
Inpatient admissions were identified from MedPAR files, and ED visits were identified from 
the Inpatient, Outpatient, and Carrier SAF, using procedure codes (99281–99285); (3) 
inhospital death; and (4) use of hospice care, as identified from the hospice SAF.
Each of the above measures were binary (0/1) variables for receipt of cancer-directed 
treatment, hospitalizations and/or ED visits, in-hospital death, and hospice use, respectively.
5.2. Main Independent Variables
Our main independent variables included race, defined as non-Hispanic Blacks (NHBs) vs 
all others, and multimorbidity (MM). Consistent with our previous study [25], we defined 
MM as the co-occurrence of chronic conditions (CC), functional limitations (FL), and/or 
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geriatric syndromes (GS). These measures were identified from the last HRS wave 
preceding death.
MM was constructed in two steps: first, we identified the presence of absence of each of CC, 
FL, and GS, as three different dichotomous variables. The presence or CC was determined 
based on whether the respondent “was ever told by a doctor that” s/he had one of seven 
chronic conditions: high blood pressure, heart disease, lung disease, stroke, arthritis, or 
psychiatric illness. The presence of FL based on whether “[b]ecause of a health [or memory] 
problem” the respondent had any difficulty performing four or more standard mobility, 
strength, activities of daily living, or instrumental activities of daily living (out of 21 
possible). Respondents were instructed to exclude any difficulties expected to last less than 
three months. GS are conditions commonly experienced by older adults that fall outside of 
the chronic disease paradigm [28]. We determined the presence of GS based on whether the 
respondent had one or more of the following: vision impairment (eyesight rated as poor or 
fair even when wearing “corrective lenses as usual” or was legally blind); hearing 
impairment (hearing rated as fair or poor even when “using a hearing aid as usual”); 
moderate or severe depressive symptoms (4 or more modified 8-item Center for 
Epidemiologic Studies Depression Scale [CES-D] [29]); urinary incontinence; low cognitive 
performance (bottom third of a 35-point scale, designed to measure working memory, 
mental processing speed, knowledge and language, and orientation [30]); persistent 
dizziness or lightheadedness; or severe pain (“often troubled”) [31].
Next, we summed the binary indicators of CC, FL, and GS to create the ordinal measure of 
MM, ranging from 0 to 3. Thus, MM0–MM3 were defined as follows: MM0: no chronic 
conditions, functional limitations, or geriatric syndromes (reference category); MM1: 
presence of any one of chronic conditions, functional limitations, or geriatric syndromes; 
MM2: co-occurrence of any two of chronic conditions, functional limitations, or geriatric 
syndromes; and MM3: co-occurrence of all three of chronic conditions, functional 
limitations, and geriatric syndromes. Because of the small number of respondents with 
MM0, we combined the MM0 and MM1 categories as MM0/1.
5.3. Other Independent Variables
5.3.1. Sociodemographic Variables—They included age (in 5-year increments 66–69, 
70–74, 75–79, 80–84, 85+); sex (male and female); marital status (married, divorced, 
widowed, never married); education (<9 years, 9–11 years, 12 years, 13–15 years, 16 years, 
17+ years); and income (in quartiles).
The anatomic tumor site was identified from the underlying cause of death documented in 
the NDI. Based on the distribution shown in Table 1, we further grouped them in the 
following categories: trachea, bronchus, and lung; pancreas; colorectal; breast (female); 
hematologic cancers; and all others.
6. Analytic Approach
In addition to descriptive analysis, we conducted multivariable logistic regression analysis to 
analyze the association of each of the social determinants of health and MM (or components 
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thereof) in relation to hospice use, after adjusting for other patient characteristics. We also 
tested the significance of interaction terms. Since none of these terms proved to be 
statistically significant, we present the findings from the models that did not include 
interaction terms. Our multivariable models accounted for income, but not for education, 
given that the two variables are highly correlated. In addition, while our composite measure 
for MM did not prove to be significantly associated with the outcomes, the components of 
MM did—at least with some of the outcomes.
For parsimony, we present findings from the final models only.
We used SAS version 9.2 for all of our analyses.
7. Results
The distribution of our study population (n = 835) by sociodemographic variables and MM 
is presented in Table 1. Nearly 12% were non-Hispanic Black; 51.3% were women; 44.2% 
were 80 years of age or older; 53.5% were married; and 27.2% had at least some college. 
Nearly 60% presented with MM3, i.e., with co-occurring chronic conditions, functional 
limitations, and geriatric syndromes. A total of 25% died from trachea, bronchus, or lung 
cancer; 10.5% from hematopoietic cancers; 9.7% from colorectal cancer; and 5.6% from 
(female) breast cancer.
Fig. 1 presents results from the bivariate association between each of the social determinants 
of health and our outcomes of interest. The percentage of patients receiving cancer-directed 
treatment declined significantly with older age, but increased significantly with higher 
education and income, in a “J-shaped” distribution. There was no significant difference by 
race/ethnicity. Admission to the ED and/or acute care hospital was significantly lower in 
older patients, but higher among non-Hispanic Blacks than in others; no significant 
differences were observed by income or education. Enrollment in hospice was significantly 
lower in non-Hispanic Blacks than in others, but generally higher with higher levels of 
income or education; it was not associated with age. In-hospital death was significantly 
higher in non-Hispanic Blacks than in others. More interestingly, we observed a “U-shaped” 
distribution between in-hospital death and each of income and education. Older age was not 
associated with in-hospital death.
We note that both sex and marital status, important social determinants of health, were not 
associated with any of our outcomes. For parsimony, we opted not to present these variables 
in our figures.
Fig. 2 shows variations in the measures of interest by anatomic cancer site. Except for 
cancer-directed treatment, all other variations were statistically significant. Receipt of 
cancer-directed treatment was lowest among breast patients with cancer (8.5%) and highest 
among those with trachea, bronchus, and lung cancer (27.8%). Both admission to hospital 
and/or ED and in-hospital death were highest in patients with hematopoietic cancers (70.5% 
and 45.5%, respectively). Enrollment in hospice was highest in patients with breast cancer 
(76.6%), and lowest in patients with hematopoietic cancers (39.8%).
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Fig. 3 presents results from the bivariate association between our outcomes of interest, the 
composite measure of MM, and each of its components. Receipt of cancer-directed 
treatment was significantly lower among patients with high MM. Among its components, 
higher counts for each of functional limitations and geriatric syndromes—but not for chronic 
conditions—were negatively associated with receipt of treatment. MM or its components 
were not associated with any of the other outcomes.
Table 2 presents the results from the multivariable analysis. With the following exceptions, 
the findings are consistent with that of the bivariate associations described above: First, non-
Hispanic Blacks were more likely than others to receive cancer-directed treatment but the 
association was borderline significant (adjusted odds ratio (AOR): 1.71, 95% confidence 
interval (1.02, 2.86), p = 0.04). Second, the composite measure of MM was not associated 
with any of our outcomes; we therefore present findings from the models incorporating the 
MM components. Here, we note that a higher count of functional limitations was no longer 
associated with receipt of cancer-directed treatment; however, presenting with 3 or more 
geriatric syndromes was significantly associated with a lower likelihood of undergoing 
treatment for cancer (AOR: 0.54 (0.32, 0.98)). In addition, presenting with 3 or more chronic 
conditions was associated with a greater likelihood to be admitted to acute care hospital or to 
the ED, but at borderline significance (AOR: 1.77 (1.05, 2.99)).
8. Discussion
This study, analyzing end-of-life care in a representative sample of older adults dying from 
cancer, investigated correlates of aggressive care and hospice use in the weeks preceding 
death. In addition to social determinants of health, we also accounted for MM, which is a 
measure that has seldom been accounted for in previous studies. We hypothesized that 
aggressive end-of-life care was independently associated with each of social determinants of 
health and MM.
Our findings indicated that the association between patterns of end-of-life care and each of 
social determinants of health and MM was highly complex, and that these associations 
varied greatly across the outcomes being studied. Findings of particular interest include the 
J-shaped and U-shaped distribution between income and each of receipt of cancer-directed 
treatment and in- hospital death, respectively, reflecting a non-linear association that has not 
been described previously. In addition, with the exception of cancer-directed treatment, we 
observed marked and statistically significant variations in our outcomes by anatomic cancer 
site. On the other hand, similar to prior studies, we also report that being non-Hispanic 
Black and having low incomes was associated with significantly lower likelihood to enroll in 
hospice [17, 32]. Surprisingly, patient sex and marital status were not associated with our 
outcomes of interest.
With regard to MM, our composite measure of MM was not associated with our outcomes. 
Similarly, limitations in functional status were not significantly associated with our 
outcomes in multivariable models. On the other hand, we noted that a higher count of 
geriatric syndromes was associated with a significantly lower likelihood to receive cancer-
directed treatment, and a higher count of chronic conditions was associated with a greater 
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likelihood to have ED visits or hospital admissions. Our small sample size precluded us 
from being able to include individual clinical conditions in our multivariable model; 
however, a recent study [32] failed to show any association between use of hospice care and 
cognitive decline, one of the conditions that we accounted for among geriatric syndromes.
These findings call for the development of tailored interventions to educate patients and their 
families on the benefits of palliative care and hospice, based on the above-noted variations 
by age, race/ethnicity, income, anatomic cancer site, and MM. Such interventions would not 
only affect quality of life, but they would also result in substantial savings to the health care 
system. A recent study from Canada reported that patients with cancer receiving aggressive 
end-of-life care incur 43% higher costs in their final month of life compared to their 
counterparts who are not managed aggressively [3]. Furthermore, to achieve the desired 
reductions in the cost of care, palliative care should be offered to patients with metastatic 
cancer earlier (more than 90 days prior to death), rather than later [33].
An important new development is the Medicare Care Choices program, which was launched 
by the Centers for Medicare & Medicaid Services (CMS) on January 1, 2016 [34]. Through 
this 5-year program, patients with terminal illness will be able to receive hospice care while 
also receiving chemotherapy. Although the effect of this program on patterns of end-of-life 
care remains to be seen, it is possible that when cancer treatment is no longer withheld, it 
may be easier for patients and families to decide to enroll in hospice, and possibly even 
gradually decrease chemotherapy.
Our study's main strength lies in our use of a unique database, which combines self-reported 
data from the HRS, claims-based measures from Medicare administrative data, as well as 
death data on a U.S. representative sample of older adults dying from cancer. In addition, by 
incorporating functional limitations and geriatric syndromes in our measure of MM, our 
study expands beyond the simple count of chronic conditions that are derived from claims 
data, to more comprehensively capture the complex clinical presentation of older patients 
with cancer. Findings from our recent work in this area support drawing a clear distinction 
between multiple chronic conditions and MM. Indeed, in a recent study using predictive 
analytic techniques to identify predictors of health outcomes [35], including self-reported 
health status, self-reported worse health in two years, and two-year mortality, we 
demonstrated that the drivers of health outcomes are not necessarily chronic conditions, but 
functional limitations and geriatric syndromes. This highlights the importance of accounting 
for the latter conditions and the nuance that they add to the interpretation of our findings 
when we include them in our studies, compared to when we limit ourselves to chronic 
conditions.
Our study also presents limitations. First, we were unable to account for the patient-centered 
measures (e.g., knowledge, preference) and/or providers' attitudes regarding end-of-life care. 
Second, rather than care in real-time, our end-of-life care measures are retrospective, and the 
patients in our cohort may not have seemed to be nearing death at the time care was rendered 
[36]. However, since our study population was identified based on the cause of death in the 
NDI, and our outcomes reflect care received in the weeks preceding death, we believe that 
our results accurately capture patterns of end-of-life care in older patients with cancer. Third, 
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some of the treatment modalities (e.g., radiation therapy) may have been administered as 
part of palliative care. Fourth, since we were unable to access Part D data and account for 
oral agents, our measure of cancer-directed treatment may have been underestimated. Fifth, 
to be consistent with how we identified functional limitations and geriatric syndromes, we 
retrieved chronic conditions from the HRS as well, thus limiting them to the seven self-
reported chronic conditions (in addition to cancer). Findings from studies identifying 
comorbid chronic conditions based on claims-based algorithms may differ from that of this 
study [37]. Lastly, we note that there may be inaccuracies and miscoding in the cause of 
death documented in death certificates, with over-representation of coronary heart disease as 
a cause of death, especially in older persons [38]. Furthermore, inaccuracies and miscoding 
may vary across anatomic cancer sites, as documented by Polednak [39–42]. These 
inaccuracies may be due to insufficient knowledge of the decedent's medical history by the 
certifier [42]. Others, however, have reported high-level agreement between the underlying 
cause of death and medical records, as was the case in studies in prostate patients with 
cancer [43,44]. Also, in contrast to our use of the underlying cause of death to identify 
patients dying from cancer, future studies should explore the utility of using multiple causes 
of death, as documented in a study on deaths from myelodysplastic syndromes [45].
In conclusion, our findings underscore the significant and complex role that social 
determinants of health and MM play in the patterns of end-of-life care, and that 
interventions to curtail aggressive care and high costs incurred by dying patients should be 
tailored to the social and clinical contexts in which patients with terminal cancer present. 
Future studies should focus on identifying specific combinations of conditions with and 
across the rubrics of social determinants and MM that are associated with patterns of end-of-
life care to aid with the development of interventions targeting subgroups of geriatric 
patients with cancer who are at high risk to receive aggressive end-of-life care.
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Appendix A. Procedure codes to capture cancer-directed treatment
Cancer-directed surgery for common cancers [1]:
Procedure type ICD-9 procedure codes CPT/HCPCS codes
Lung cancer
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Procedure type ICD-9 procedure codes CPT/HCPCS codes
    Biopsy 33.24-33.38, 34.02-34.27, 34.10-34.19, 
34.21, 40.11
31625, 31628, 31629, 32095, 32405, 32602, 
32606, 39000, 39010, 39400, 76360
    Local excision 32.28 31640, 31641
    Resection 32.29, 32.3-32.99 32440-32525, 32657, 32663
Breast cancer
    Biopsy 85.11, 85.12 19100, 19101
    Local excision 85.20-85.22 19125, 19126, 19160, 19162
    Resection 85.23, 85.41-85.48 19180-19240
Prostate cancer
    Biopsy 60.11, 60.12 55700, 55705, 76360
    Local excision 60.2-60.49 52601, 52612-52650, 55801, 55831
    Resection 60.5-60.59, 62.4-62.42 54520, 54530, 55810-55815, 55840-55845
Endometrial cancer
    Biopsy 68.13, 68.16, 69.09 58100-58120
    Local excision 68.3-68.59, 68.9-68.99, 65.3-65.69 58150, 58180-58200, 58260-58262
    Resection 68.6, 68.7, 68.8-68.89 58210, 58240, 58285
Colorectal cancer
    Biopsy 45.25, 45.26, 48.24, 48.25 44389, 45305, 45331, 45390, 76360
    Local excision 45.41-45.49, 48.31-48.35 44110, 44392-44394, 45160-45180, 45308, 45309, 
45315, 45320, 45333, 45338, 45339, 45383-45385
    Bypass surgery 46.01, 46.03, 46.10-46.24 44310, 44320




    Biopsy 52.11, 52.12, 52.14 43261, 48100, 48102, 76360
    Local excision 52.2-52.22 48120, 48145, 48148
    Bypass surgery 44.39, 51.36, 51.39, 51.42 43820, 43825, 47720-47780
    Resection 52.5-52.79 48140-48144, 48146, 48147, 48149-48155
Chemotherapy (Adapted from Earle et al. 2008) [2]: ICD-9 Diagnosis V58.1, V66.2, V67.2; ICD-9 procedure code: 99.25; 
HCPCS codes: 964XX, 965XX Q0083-Q0085; J7150, J85XX, J86XX, J87XX, J8999, J9XXX, Q0083, Q0084, Q0085.
Radiation therapy (Adapted from Earle et al. 2008) [2]: ICD-9 diagnosis codes: V58.0, V66.1, V67.1; ICD-9 procedure 
codes: 92.21-92.29; HCPCS codes: 77401-77499, 77750-77799; Revenue center codes: 0330, 0333.
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Table 1
Distribution of the study population by social determinants of health and multimorbidity.
Variables of interest Total study population N (% of total)
Number with outcome 835 (100.0)
Race
    Black 99 (11.9)
    All other 736 (88.1)
Age
    66-69 105 (12.6)
    70-74 169 (20.2)
    75-79 192 (23.0)
    80-84 190 (22.8)
    85 + 179 (21.4)
Sex
    Male 407 (48.7)
    Female 428 (51.3)
Marital status
    Married 447 (53.5)
    Single/widowed/divorced *
    Missing *
 (< 2.0)
Education
    At least some college 227 (27.2)
    High school graduate 273 (32.7)
    High school dropout 335 (40.1)
Household income
    Lowest quartile 228 (27.3)
    2nd quartile 204 (24.4)
    3rd quartile 203 (24.3)
    Highest quartile 200 (24.0)
Count of chronic conditions
    0 85 (10.2)
    1-2 417 (49.9)
    3 or more 333 (39.9)
Count of functional limitations
    0 84 (10.1)
    1-3 208 (24.9)
    4-7 273 (32.7)
    8 or more 257 (30.8)
    Missing 13 (1.6)
Count of geriatric syndromes
    0 *
 (<17.0)
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Variables of interest Total study population N (% of total)
    1-2 474 (56.8)
    3 or more 223 (26.7)
    Missing *
Composite multimorbidity measure (MM)
    MM0/1 109 (13.1)
    MM2 262 (31.4)
    MM3 441 (52.8)
    Missing 23 (2.8)
Tumor site
    Oro-pharyngeal *
    Esophagus 17 (2.0)
    Stomach 23 (2.8)
    Colorectal 81 (9.7)
    Pancreas 59 (7.1)
    Larynx *
    Trachea, bronchus, lung 209 (25.0)
    Skin *
    Breast (female) 47 (5.6)
    Uterus 12 (1.4)
    Ovary 26 (3.1)
    Prostate 15 (1.8)
    Bladder 24 (2.9)
    Brain 15 (1.8)
    Blood 88 (10.5)
    Secondary *
    All other 190 (22.8)
*
Cell contents suppressed if n < 11. A corresponding cell in the column was suppressed to prevent the reader from deducing the masked number.
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Table 2
Multivariate adjusted outcome models.
Variables of interest Cancer-directed treatment Acute care Hospice Died in-hospital
Number of decedents with outcome 204 457 509 180
Age
    66-69 1.0 1.0 1.0 1.0
    70-74 1.08 (0.62, 1.86) 1.06 (0.63, 1.77) 0.91 (0.54, 1.56) 1.27 (0.69, 2.37)
    75-79 0.99 (0.58, 1.69) 1.17 (0.70, 1.94) 0.78 (0.47, 1.32) 1.20 (0.65, 2.19)
    80-84 0.61 (0.34, 1.10) 0.88 (0.52, 1.48) 1.01 (0.59, 1.74) 1.00 (0.53, 1.91)
    85 + 0.45 (0.23, 0.86)c 1.08 (0.63, 1.86) 1.15 (0.65, 2.02) 0.62 (0.31, 1.23)
Sex
    Male 1.0 1.0 1.0 1.0
    Female 0.99 (0.68, 1.44) 0.84 (0.61, 1.16) 1.21 (0.86, 1.69) 0.81 (0.54, 1.20)
Race
    Black 1.71 (1.02, 2.86)a 2.05 (1.24, 3.38)c 0.48 (0.30, 0.77)c 1.88 (1.13, 3.16)a
    All other 1.0 1.0 1.0 1.0
Marital status
    Married 1.0 1.0 1.0 1.0
    Divorced 1.38 (0.75, 2.55) 1.03 (0.58, 1.82) 1.05 (0.59, 1.88) 1.38 (0.73, 2.61)
    Widowed 1.12 (0.73, 1.70) 0.96 (0.67, 1.37) 1.13 (0.78, 1.64) 1.03 (0.66, 1.59)
    Never married 0.68 (0.18, 2.59) 0.99 (0.35, 2.79) 0.70, 0.25, 1.98) 0.51 (0.11, 2.41)
Household income
    Lowest quartile 1.12 (0.67, 1.88) 1.59 (1.04, 2.45) 0.44 (0.28, 0.70)c 2.17 (1.25, 3.76)a
    2nd quartile 1.03 (0.63, 1.69) 1.25 (0.83, 1.88) 0.61 (0.40, 0.94) 1.40 (0.81, 2.42)
    3rd quartile 1.0 1.0 1.0 1.0
    Highest quartile 1.77 (1.11, 2.83)a 1.27 (0.84, 1.91) 0.84 (0.54, 1.30) 1.91 (1.13, 3.22)c
Count of chronic conditions
    0 (ref) 1.0 1.0 1.0 1.0
    1-2 1.22 (0.86, 3.01) 1.61 (0.98, 2.64) 1.06 (0.63, 1.77) 1.17 (0.62, 2.20)
    3 or more 1.61 (0.86, 3.01) 1.77 (1.05, 2.99)a 1.09 (0.63, 1.88) 1.21 (0.62, 2.37)
Count of functional limitations
    0 (ref) 1.0 1.0 1.0 1.0
    1-3 0.99 (0.55, 1.80) 1.04 (0.61, 1.79) 1.16 (0.67, 2.02) 0.84 (0.44, 1.61)
    4-7 0.96 (0.53, 1.72) 1.00 (0.58, 1.70) 1.07 (0.62, 1.86) 0.94 (0.50, 1.77)
    8 or more 0.57 (0.30, 1.10) 0.77 (0.44, 1.36) 1.27 (0.71, 2.28) 0.74 (0.37, 1.48)
Count of geriatric syndromes
    0 (ref) 1.0 1.0 1.0 1.0
    1-2 0.70 (0.45, 1.08) 1.04 (0.69, 1.57) 1.13 (0.74, 1.73) 1.16 (0.69, 1.95)
    3 or more 0.54 (0.31, 0.94)a 0.93 (0.57, 1.50) 0.92 (0.56, 1.52) 1.38 (0.75, 2.54)
Tumor site
    Trachea, bronchus, lung 1.14 (0.75, 1.73) 1.19 (0.83, 1.71) 1.56 (1.07, 2.29)a 0.59 (0.37, 0.95)a
    Pancreas 1.02 (0.51, 2.05) 0.61 (0.34, 1.11) 1.65 (0.87, 3.13) 0.56 (0.25 (1.27)
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Variables of interest Cancer-directed treatment Acute care Hospice Died in-hospital
    Blood 1.12 (0.65, 1.95) 2.06 (1.23, 3.46)c 0.41 (0.25, 0.68)b 3.05 (1.82, 5.10)c
    Colorectal 1.09 (0.61, 1.96) 0.62 (0.38, 1.03) 1.41 (0.83, 2.38) 0.75 (0.39, 1.41)
    Breast (female) 0.36 (0.12, 1.07) 0.96 (0.50, 1.85) 2.23 (1.05, 4.71)a 0.80 (0.34, 1.87)
    All other 1.0 1.0 1.0 1.0
P-values are denoted as superscripts (a) 0.01 ≤ p ≤ 0.05; (b) 0.0001 ≤ p < 0.01; (c) p < 0.0001.
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